Janux TherapeuticsJANX
JANX
About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Employees: 76
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
7% more capital invested
Capital invested by funds: $1.94B [Q2] → $2.07B (+$136M) [Q3]
4% more funds holding
Funds holding: 153 [Q2] → 159 (+6) [Q3]
2% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 51
1.69% less ownership
Funds ownership: 89.18% [Q2] → 87.49% (-1.69%) [Q3]
86% less call options, than puts
Call options by funds: $4.14M | Put options by funds: $29.8M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$62
38%
upside
Avg. target
$108
140%
upside
High target
$200
346%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Cantor Fitzgerald Josh Schimmer 37% 1-year accuracy 22 / 59 met price target | 346%upside $200 | Overweight Reiterated | 11 Dec 2024 |
Scotiabank George Farmer 15% 1-year accuracy 3 / 20 met price target | 38%upside $62 | Sector Perform Maintained | 4 Dec 2024 |
Stifel Bradley Canino 19% 1-year accuracy 6 / 32 met price target | 156%upside $115 | Buy Maintained | 3 Dec 2024 |
Leerink Partners Jeffrey La Rosa 0% 1-year accuracy 0 / 2 met price target | 103%upside $91 | Outperform Maintained | 3 Dec 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 29% 1-year accuracy 56 / 190 met price target | 56%upside $70 | Buy Maintained | 3 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer.
Positive
Seeking Alpha
4 weeks ago
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance sheet, with $658.1 million in liquid assets and no debt. Oppenheimer identified Janux as a top biotech buyout candidate for 2025, citing its innovative platform and promising.
Positive
Seeking Alpha
1 month ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Neutral
Business Wire
1 month ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of.
Neutral
Business Wire
2 months ago
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas.
Positive
The Motley Fool
2 months ago
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.
Positive
Zacks Investment Research
2 months ago
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
Neutral
Business Wire
2 months ago
Janux Therapeutics Announces Proposed Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.
Positive
Benzinga
2 months ago
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
On Monday, Janux Therapeutics, Inc. JANX revealed updated interim clinical data for its JANX007 clinical program.
Positive
Barrons
2 months ago
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.
Charts implemented using Lightweight Charts™